Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Current Liabilities
All obligations due within one year.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 58.8% from a year ago
Total current liabilities stood at $26.49M at the end of Q1 FY2026, up 58.8% from a year earlier and up 39.9% from the prior quarter. Over 3 fiscal years it compounded at +79.3% a year.
Context
- Total current liabilities amounted to 41.1% of total assets at the end of Q1 FY2026, down 18.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +58.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 18.94M USD
- Year-over-year change
- -21.5%
- 4-year CAGR
- +73.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.94M | -21.5% |
| FY2024 | 2024-12-31 | 24.12M | +37.6% |
| FY2023 | 2023-12-31 | 17.53M | +433.9% |
| FY2022 | 2022-12-31 | 3.28M | +56.0% |
| FY2021 | 2021-12-31 | 2.11M | — |
Total Current Liabilities vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +58.8% is the 3rd highest of 10, against a peer median of -18.4%.
- Total current liabilities amounts to 41.1% of total assets for UNCY, versus a peer median of 15.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $76.84M USD | -22.0% | +69.2% | 42.7% | |
| Mar 2026 | $38.36M USD | +49.9% | +32.8% | 20.2% | |
| Mar 2026 | $26.49M USD | +58.8% | +79.3% | 41.1% | |
| Mar 2026 | $16.62M USD | +158.1% | — | 15.8% | |
CBUSCibus, Inc. | Mar 2026 | $13.94M USD | -33.6% | +116.5% | 4.3% |
| Mar 2026 | $12.89M USD | +146.4% | -19.8% | 5.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $11.05M USD | -18.4% | +34.0% | 10.3% |
| Mar 2026 | $9.29M USD | -53.1% | -16.5% | 20.0% | |
| Mar 2026 | $8.6M USD | -11.9% | +1.8% | 8.9% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$5.07M CAD | -43.3% | -0.9% | 21.9% |
| Peer median (excluding UNCY) | — | -18.4% | +17.3% | 15.8% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.